ABSTRACT: Heterotopic ossification (HO) is a debilitating sequela of high-energy injuries. It frequently requires surgical excision once symptomatic and there is no practical prophylaxis for combat-injured patients. In this study, we examined the effect of local vancomycin powder on HO formation in a small animal model of blast-related, post-traumatic HO. Male Sprague-Dawley rats were subjected to a polytraumatic extremity injury and amputation with or without methicillin-resistant Staphylococcus aureus infection. Animals were randomized to receive a single local application of vancomycin (20 mg/kg) at the time of injury (POD-0, n ¼ 34) or on postoperative day-3 (POD-3, n ¼ 11). Quantitative volumetric measurement of ectopic bone was calculated at 12-weeks post-injury by micro-CT. Bone marrow and muscle tissues were also collected to determine the bacterial burden. Blood for serum cytokine analysis was collected at baseline and post-injury. Vancomycin treatment on POD-0 suppressed HO formation by 86% and prevented bone marrow and soft tissue infections. We concurrently observed a marked reduction histologically in nonviable tissue, chronic inflammatory cell infiltrates, bone infection, fibrous tissue, and areas of bone necrosis within this same cohort. Delayed treatment was significantly less efficacious. Neither treatment had a marked effect on the production of pro-inflammatory cytokines. Our study demonstrates that local vancomycin treatment at the time of injury significantly reduces HO formation in both the presence and absence of infection, with decreased efficacy if not given early. These findings further support the concept that the therapeutic window for prophylaxis is narrow, highlighting the need to develop early treatment strategies for clinical management. ß
Heterotopic Ossification (HO) is the development of mature lamellar bone in non-osseous tissue. The pathologic condition develops following hip arthroplasty, neurologic injury (including spinal cord injuries and traumatic brain injury), burn injuries, as well as elbow, and acetabular fractures. 1 Up to 65% of combat-injured personnel recovering from blast injuries develop HO, most commonly within the residual limbs of amputees. [2] [3] [4] High energy trauma increases the presence of osteogenic progenitors within damaged adipose tissue and skeletal muscle of HO patients 5, 6 and is associated with elevated expression of mRNAs encoding extracellular matrix, chondro-angio-osteogenic proteins as well as inflammatory cytokines and chemokines. 7, 8 The development of HO following injury can cause substantial morbidity for patients and once established, symptomatic HO has few treatment options. Surgical excision remains the only treatment for persistently symptomatic HO, and can itself be associated with substantial morbidity in terms of blood loss, subsequent infection, and rehabilitation delays. 2, 4, [9] [10] [11] Given the impact of HO formation on afflicted patients, prophylactic measures are frequently employed. Existing measures include external beam radiation therapy and non-steroidal anti-inflammatory medications, such as indomethacin. Unfortunately, neither modality is well suited to use in the multiply injured, combat wounded patient. 12 Alternative strategies are thus needed to decrease the occurrence and morbidity of HO in this population. The ideal prophylaxis modality would be well tolerated in a multiply injured patient, possess minimal deleterious side effects, and lend itself readily to early deployment in an austere environment, all while remaining cost-effective.
In an effort to evaluate various means of primary prophylaxis, our group established and characterized a small animal model for post-traumatic HO. The intent is to simulate the physiologic insults associated with extremity blast injuries, including blast overpressure, femur fracture, thigh muscle crush injury, and amputation through the zone of injury. In this manner, we have observed ectopic bone formation in a reliable and reproducible manner. [12] [13] [14] [15] We have also demonstrated that concurrent inoculation of the wound with methicillin-resistant Staphylococcus aureus (MRSA) increases the volume of HO formation using this model. 14 The effect of bioburden on the formation of ectopic bone may be due to differential Toll-like receptor (TLR) signaling or the presence of an altered, persistently proinflammatory milieu which drives stem cell chondrogenesis, facilitating subsequent ossification. that enhancing the local antimicrobial environment may facilitate normalization of host-immune response and mitigate the formation of HO. We selected vancomycin, a glycopeptide antibiotic, for application within the simulated combat-related amputation. Vancomycin inhibits bacterial cell wall synthesis and is frequently used as empiric therapy for Gram-positive coverage and definitive therapy when MRSA infection is suspected or confirmed. Vancomycin was chosen because of its activity against MRSA, its reported efficacy in preventing surgical site infections in spine and orthopaedic trauma patients [17] [18] [19] and because it has been well tolerated during extensive use in the combatwounded population.
With this in mind, we asked whether vancomycin application would decrease HO formation following a polytraumatic extremity injury in this small animal model. Additionally, we sought to characterize the effect of local vancomycin application on the systemic inflammatory response associated with bacterial inoculation. Specific aims of this experiment include volumetric quantification of ectopic bone formation by micro-Computerized Tomography (micro-CT), histological assessment of the residual limb, bacterial load quantification, and serial serum cytokine analysis at various time points post injury.
METHODS

Animals
A total of 103 young adult pathogen-free male SpragueDawley rats (Rattus norvegicus; 12-14 weeks, 400-500 g) were purchased from Taconic Farms (Germantown, NY). All animals were housed in clean plastic cages and kept on a 12-h light/dark cycle with unlimited access to food (standard rodent chow) and fresh water ad libitum. Body weight was monitored before and twice weekly after surgery and prior to necropsy. The study protocol (15-OUMD-19S) was reviewed and approved by the Walter Reed Army Institute of Research/Naval Medical Research Center Institutional Animal Care and Use Committee in compliance with all applicable Federal regulations governing the protection of animals in research.
Trauma-Induced Rat HO Model and Vancomycin Application Rats were subjected to blast overpressure exposure, a femur fracture, soft tissue crush injury, and limb amputation through the zone of injury as previously described. 13 Following injury, all animals initially underwent appropriate d ebridement of devitalized tissue. Wounds were then treated with 20 mg/kg of vancomycin powder (Mylan N.V., Canonsburg, PA) either at the time of injury (POD-0) or 3 days post-injury (POD-3) or a myoplasty was performed without vancomycin treatment (Fig. 1 ). An additional five animals were used as controls for cytokine analysis and were not subjected to injury. Vancomycin powder was applied to the exposed muscle tissue and residual end of the amputated femur following irrigation of the wound and establishment of hemostasis. Next, a myoplasty of the quadriceps, hamstrings, and adductors was performed with 3-0 Vicryl (Ethicon, LLC. Cincinnati, OH) over the exposed residual femur, followed by inoculation of the muscle sites surrounding the amputation site with: (1) 100 ml of PBS; or (2) MRSA strain 107261 (100 ml of 1 Â 10 7 CFU) which is a virulent strain isolated from combat-injured personnel treated at Walter Reed National Military Medical Center. 14 The wound was closed using a 3-0 Vicryl (Ethicon) in the deep subcutaneous tissue, followed by a running 4-0 subcuticular Monocryl (Ethicon). The incision was then reinforced with 2-0 Ethilon Nylon (Ethicon) and sealed with a dermal adhesive, Vetbond (3M Animal Care Products, St Paul, MN). For wounds treated with vancomycin powder at POD-3, the incision was opened and the myoplasty taken down. The wound was then irrigated, vancomycin powder was applied, and the wound closed in a similar fashion as before. Based on existing literature the dose of vancomycin powder used in these studies is similar to concentrations used in human applications and below overtly cytotoxic levels. [20] [21] [22] [23] Postoperative pain was managed using sustained-release buprenorphine (1.2 mg/kg) administered subcutaneously on the day of surgery with repeat dosing after 72 h, if needed, as previously described. 13 Postoperatively, rats were monitored at least twice daily by animal care staff, research investigators, and veterinarians for activity, signs of pain, weight loss, wound dehiscence, or sinus tracts for the duration of the study. Wounds that exhibited signs of infection (defined as drainage or progressive marginal erythema) or overt dehiscence were irrigated, d ebrided, and closed. Rats were euthanized if they demonstrated failure to thrive, persistent signs of infection, or wound dehiscence after a third d ebridement. At study endpoint (POD-84), or if early euthanasia criteria were met, rats were euthanized with pentobarbital (Fatal Plus; 390 mg/kg intraperitoneally; Patterson Veterinary, Devens, MA).
Micro-CT Analysis
Rats were anesthetized with isoflurane (2-4%) and imaged at POD-84 using a SkyScan 1176 in vivo high-resolution micro-CT (Bruker-MicroCT, Kontich, Belgium) with the following settings: 89-kV polychromatic X-ray beam, current of 256 mA, and an exposure time of 81 m/sec for each of 180 rotational steps. Three investigators (JGS, GJP, and ATQ) independently reviewed the micro-CT images (170-200 flattened longitudinal micro-CT slices/rat) on a CT-Analyser (Bruker-MicroCT) and calculated the volume of ectopic bone formation using selected regions of interest on every fifth slice encompassing ectopic bone. The selected slices were used to generate a threedimensional volume of interest, which was analyzed for the total volume of bone within the selected area.
14, 15 The minimal detectable volume of ectopic bone was 0.05mm 3 . The effect of vancomycin treatment on orthotopic bone formation was determined by measuring the cortical thickness of the ipsilateral femur 5 mm below the level of the lesser trochanter.
Bacteriology
Following euthanasia at POD-84, soft tissue and bone marrow samples were collected for bacterial quantification.
14 Briefly, the bone marrow content of the residual femur was flushed using sterile D-PBS and muscle tissue surrounding the site of amputation was collected aseptically. Tissues were homogenized and suspended in D-PBS. Estimation of bacterial colony forming units (CFU) was made through serial dilution plating on blood agar plates, and incubated overnight at 37˚C with 5% CO 2 . Colonies were then counted and screened for differing morphology. Isolates were streaked on a blood agar plate for direct bacterial species identification using the BD Phoenix automated microbiology system (BD Diagnostics, Sparks, MD) in accordance with the manufacturer's instructions. We recorded results both as an average CFU per group in soft tissue and bone marrow as well as the number of samples with detectable bacteria per group.
Histological Analysis
Following euthanasia, animals underwent en bloc resection of the residual limb by hip-disarticulation. The residual limb was fixed in 10% formalin, decalcified in 5% formic acid, paraffin-embedded, cut into 5-mm sections on a microtome, and stained using hematoxylin and eosin stain (Histoserv Inc., Germantown, MD). Histologic tissue samples were qualitatively analyzed for evidence of soft tissue cartilage formation, inflammation, lamellar bone formation within the soft tissues, the presence of persistent inflammatory cells, or active bacterial infection. The histopathological analysis was conducted by a veterinary pathologist (MAH) blinded to the treatment groups.
Blood Collection and Serum Cytokine Analysis
Blood was collected from rats at 3, 6, 9, 12, 24, and 36 h and at 5, 7, 10, 28, and 84 days post-operatively by serial tail bleeds from MRSA infected rats AE vancomycin treatment initiated on POD-0. Serum from five aged-matched, naïve rats was used for baseline measurements. Serum inflammatory mediators were measured using Luminex (Luminex Corporation, Austin, TX) multianalyte profiling technology (Bio-Plex Pro TM rat cytokine assay kit; Bio-Rad Laboratories, Hercules, CA) according to the manufacturer's instructions. The concentrations of nine host markers including: Interleukin (IL)-1b, IL-6, IL-10, IL-12p70, IL-17, macrophage inflammatory protein (MIP)-1a, RANTES (regulated on activation, normal T cell expressed and secreted), tumor necrosis factor (TNF)-a, and monocyte chemoattractant protein (MCP)-1 were measured. The concentrations of all the analytes in the quality control reagents were found to be within the expected range. Results were extrapolated from each standard curve for each analyte.
Rat Muscle-Derived Mesenchymal Stem/Stromal Cell Isolation Rat muscle-derived mesenchymal stem/stromal cells (rMSCs) were isolated from gastrocnemius-soleus complexes from three 12-week old male Sprague-Dawley rats. Collected muscle tissue was pooled, thoroughly minced using sterile fine scissors and then enzymatically digested in Dulbecco's phosphate-buffered saline (D-PBS) containing 0.2% collagenase Type 2 (Worthington, Biochemical Corp., Lakewood, NJ), 100 U/ml DNase (Sigma-Aldrich, St. Louis, MO), and 2.5 mM CaCl 2 at 37˚C for 45 min. Digested muscle slurries were mixed with D-PBS containing 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin (antibiotics) to stop enzymatic digestion and were passed consecutively through 70 mm, followed by 40-mm nylon mesh cell strainers (BD BioSciences, San Jose, CA). RBCs were lysed by incubating filtered cells in 5 ml ACK lysis buffer (Lonza Biosciences) for 5 min, followed by washing cells with ice-cold D-PBS. The RBC-depleted, filtered cells were seeded into 75 cm 2 tissue culture flasks at a density of 2.5 Â 10 4 cells per cm 2 in growth media (Dulbecco's modified Eagle's medium [DMEM]) supplemented with 10% defined-FBS (Hyclone, Sigma-Aldrich, St. Louis, MO), and antibiotics. After 48 h of culture at 37˚C, 5% CO 2 and 100% humidity, non-adherent cells were removed and complete medium exchanges were performed every 3-4 days until the cultures were 80-90% confluent. Adherent cells were washed twice with D-PBS and the cells were harvested using 0.25% trypsin (Invitrogen, Rockville, MD) for 3-5 min, centrifuged and then replated in growth medium. Osteogenic and adipogenic differentiation were induced using confluent rMSCs (passage-3). Cells were seeded in 6-well plates and cultured for 14 days in osteogenic medium (low glucose DMEM supplement with 10% FBS, 100 nM dexamethasone, 0.05 mM ascorbate-2-phosphate, 10 mM b-glycerophosphate (Sigma-Aldrich) and antibiotics) and adipogenic medium (DMEM low glucose, 10% FBS, 0.5 mM isobutyl-methylxanthine, 10% FBS, 0.5 mM isobutyl-methylxanthine, 1 mM dexamethasone, 10 mM insulin, 200 mM indomethacin [Sigma-Aldrich] and antibiotics). Induction media was replaced every 3 days. At day 14, adherent cells were fixed with 10% formalin followed by staining with Alizarin red (Sigma-Aldrich) to detect calcified extracellular matrix and Oil Red O (SigmaAldrich) to stain lipid droplets. Microscopic examination, image acquisition, and representative photomicrographs were taken using a brightfield /fluorescence microscope at 40Â magnification (Olympus IX73 Imaging System with Olympus DP73 Universal Camera, Olympus, and Pittsburgh, PA). As shown in Figure 2 , rMSCs cultured in appropriate differentiation medium readily differentiated VANCOMYCIN SUPPRESSES TRAUMA-INDUCED HO into osteogenic and adipogenic cell lineages with the corresponding phenotypes confirmed by Alizarin red (calcium deposition) and Oil Red O stains (intracellular lipid droplet formation), respectively.
Effects of Vancomycin on MSC In Vitro Cell Proliferation
Muscle-derived rat mesenchymal stem cells (rMSCs) pooled from two donor rats, were seeded in triplicate at a density of 2.5 Â 10 2 /well in 6-well plates in normal growth media (MesenCult Basal Medium, Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg of Fungizone (Lonza, Walkersville, MD) for 24 h at 37˚C in fully humidified 5% CO 2 in air atmosphere. Normal growth media was exchanged with osteogenic media (Lonza, Walkersville, MD) containing 100 nM dexamethasone, 50 mM ascorbate-2-phosphate and varying concentrations of vancomycin (Mylan N.V., Canonsburg, PA) were added to each well (0.1-100 mg/ml) with media changes every 3 days. At the end of 6 days, adherent cell colonies were rinsed twice with PBS, fixed with 100% methanol for 5 min at room temperature, air-dried, stained with 5% WrightGiemsa stain solution for 1 min, and then rinsed with distilled water to remove residual dye. Colonies with greater than 25 cells/colony were counted using light microscopy. To assess cell viability and total cell proliferation, equal number of rMSCs was seeded in triplicates in a 6-well plate containing various doses of vancomycin in normal growth medium. In addition to an untreated control set, vancomycin was added at five different concentrations (0.1, 2.5, 10, 50, and 100 mg/ml). After 48 h of treatment, cell counts were taken using a combinatorial viability dye comprised of acridine orange and propidium iodide (Nexcelom, Lawrence, MA). The average cell count for each treatment condition was plotted, and two-tailed Student's t-test was carried out to assess any significant differences in cell counts between vancomycintreated and untreated wells.
Statistical Analysis
We performed a sample size estimation based on previous work and an expected 25% reduction in ectopic bone volume. Preliminary sample size calculations suggested that five animals would be needed per group to detect a 25% decrease in HO formation (effect size of 0.5) assuming 80% power and a ¼ 0.05. Thus, it was anticipated that nine rats in the infected treatment groups would be necessary to detect a change in ectopic bone volume, even if we encounter an attrition of up to four rats per group. We expected a low level of mortality after surgery, which was consistent with findings during model development. 12, 24, 25 Statistical analysis was performed using a two-tailed, Student's t-test. All data are presented as mean AE SEM with 95% confidence interval (CI) unless otherwise specified. Exact p-values are stated except when <0.001. Intraclass correlation coefficient (ICC) was calculated to assess the reliability of inter-observer volumetric analysis of HO formation. (Fig. 3A) . Local application of vancomycin at the time of primary wound closure (POD-0) suppressed ectopic bone formation by 86% (6.1 mm 3 AE 1.3; 95% CI ¼ 3.5-8.7, p < 0.001) in MRSA-infected rats compared to MRSA-infected, untreated rats. Furthermore, POD-0 vancomycin treatment led to a 59% reduction in ectopic bone development in noninfected rats compared to noninfected, untreated rats (6.7 mm 3 AE 1.4; 95%CI ¼ 3.9-9.4; p ¼ 0.014).
RESULTS
In contrast, initiation of vancomycin treatment at POD-3 led to similar volumes of ectopic bone formation between noninfected rats (25. All animals were able to ambulate normally within 3 days of the initial procedure. Non-MRSA infected injured rats treated with vehicle control on average gained 50.4 g over the course of the study (50.4 AE 7.1 g; 95%CI ¼ 36.5-64.2). MRSA infected injured rats treated with vancomycin at POD-0 and POD-3 gained more weight during the course of the study compared to rats administered vehicle control (84.4 AE 10.4 g; 95%CI 
Early Vancomycin Therapy Prevents Chronic Soft Tissue and Bone Infections
Long-term prevalence of MRSA musculoskeletal infection within the amputation zone (marrow cavity, subperiosteal space, periosteum, and adjacent soft tissues) was prevented by local application of vancomycin at the time of primary wound closure (Fig. 3B) . We isolated 3.0 Â 10 7 AE 1.9 Â 10 7 CFU from the soft tissue in 7 of 13 samples of untreated, MRSA-infected rats. In the same group, we isolated 4.8 Â 10 1 AE 3.2 Â 10 1 CFU from the bone marrow in 5 of 13 samples. In contrast, we observed a marked reduction in soft-tissue CFUs when vancomycin therapy started on POD-3 (1.8 Â 10 4 AE 1.8 Â 10 4 CFU in 1/5 samples) but had no effect on isolated CFU counts in the marrow compartment (6.2 Â 10 2 AE 2.8 Â 10 2 CFU in 3/5 samples). Consistent with the bacteriology, histological analysis of tissues from animals treated with vancomycin at POD-0 demonstrated a marked reduction in nonviable tissue, chronic inflammation, inflammatory cell infiltrates, subdermal abscesses, bone infection, intramedullary 
Effects of Early Local Vancomycin Treatment on Systemic Inflammation
Blast exposure combined with polytraumatic extremity injury and bacterial inoculation in our model was associated with a robust and prolonged systemic inflammatory response with significant elevations in serum cytokine/chemokine concentrations in the absence and in the presence of vancomycin treatment at the time of injury (Fig. 6 ). Compared to baseline measurements, we observed increases in the serum concentrations of IL-1b, IL-6, IL-10, IL-12p70, IL-17, TNFa, RANTES, MCP-1, and MIP-1a, which were detectable within 3 h after injury. Initial peak values were reached by 6-9 h post injury and remained elevated for 36 h. By day 5, a further wave of increases in serum IL-1b, IL-10, and TNFa was detected wherein values remained extremely high over the 84-day study period. In contrast, serum IL-6, IL-12p70, IL-17, RANTES, and MCP-1 decreased over the 12-week study; however, with the exception of IL-12p70, all of these cytokines remained significantly elevated over baseline values. Statistically significant differences were observed between the vancomycin treated and untreated groups at individual time points for IL-1b, IL-6, IL-10, MIP-1a, and MCP-1. However, none of these cytokines demonstrated significant changes in the overall trend or kinetics of their response.
Effect of Vancomycin on Rat Mesenchymal Stem Cell Proliferation
The effects of vancomycin on the survival and clonogenic proliferation of rMSC were measured using optimal osteogenic culture conditions. In vitro analysis of rMSCs showed a statistically significant increase in CFC-O counts with the addition of 2.5, 5 and 50 mg/ml of vancomycin compared to the control (162. (Fig. 7B) .
DISCUSSION
There are several key findings in this study. First, treatment with local vancomycin powder in MRSA infected animals at the time of injury leads to a significant reduction in HO formation and complete eradication of the infection within both the bone and the surrounding soft tissues. Interestingly, we observed a significant reduction in ectopic bone formation not only in wounds contaminated with MRSA but also in clean wounds that had not been inoculated with MRSA. Furthermore, delaying vancomycin treatment until POD-3 lost much of the effect on HO formation, as was the ability to clear the bacterial load; persistent infection remained in both the soft tissues and bone marrow of these animals. In the MRSA-inoculated animals treated with vancomycin on POD-0, the suppression of ectopic bone formation may be due to attenuation of local inflammatory responses via decreased microbial burden and enhanced early immunologic clearance of the infection. Biofilm formation is common among a variety of MRSA strains and can become established within 48 h. 26 Furthermore, Chopra et al. showed that vancomycin has decreased ability to eradicate older biofilms and requires higher doses of antibiotics which led to their conclusion that early treatment is necessary to eliminate MRSA. 27 When vancomycin treatment was delayed until POD-3, the bacteria became established and could not be completely cleared with a single d ebridement and vancomycin treatment. This may result in a continued inflammatory response and increased HO formation. However, reducing bioburden through the antimicrobial effects of vancomycin does not account for the reduction in HO formation seen in animals that had not been inoculated with MRSA.
A number of antibiotics have been shown to lead to significant suppression of bone marrow progenitor cells in vitro. 28 The study by Charak et al. demonstrated this effect with a variety of antibiotics including imipenem and cephalosporins. However, vancomycin was not included in the antibiotics those investigators studied and, to the best of our knowledge, no previous study has investigated the effect of vancomycin on the proliferation of mesenchymal progenitor cells. Our data does not show any significant direct anti-proliferative effect of vancomycin on purified rat MSCs at the concentrations tested. This suggests that, while vancomycin does result in suppression of HO formation, it does not appear to be through a direct effect on MSC proliferation.
In both the vancomycin treated and untreated groups, there is an early, robust, systemic immune response following injury, and bacterial inoculation. This response is already in progress by 3 h post-injury, and represents the innate immune response to tissue trauma and bacterial inoculation mediated by damage associated molecular patterns (DAMPs) and pathogen associated molecular patterns (PAMPs) acting through Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs). 29 Activation of the innate immune system by conserved self-and pathogen-associated structural motifs drives the early inflammatory response through NF-kB VANCOMYCIN SUPPRESSES TRAUMA-INDUCED HO mediated production of cytokines such as TNFa, IL-1b, IL-6, IL-8, and IL-12 by tissue macrophages, and neutrophils. 30 Bode et al. has previously reported on the immunomodulatory effects of vancomycin. 31 In their study, they used human monocytic THP-1 cells to study the effect of vancomycin on the immune response in an in vitro sepsis model. They found significant increases in the gene expression of TNF-a, IL-6, and IL-10 when the cells were cultured with vancomycin and LPS as compared to LPS alone, and noted significant increases in the expression of multiple TLRs in monocytes. The authors concluded that some antibiotics, including vancomycin, can have immunomodulatory effects and that these effects could be produced both in the presence and the absence of infection. There have also been a number of studies that have demonstrated either direct or indirect osteoclastogenic effects of certain pro-inflammatory cytokines including IL-1, IL-6, and TNF-a. [32] [33] [34] [35] This particular cytokine profile may not only increase inflammation and promote phagocytosis but may also play an inhibitory role on Th1 cells and drive the immune response to a predominately Th2 response. This altered immune response, in addition to clearing infection, may be the pathway in which vancomycin decreases HO production and would explain our finding of decreased HO formation in vancomycin treated rats in the absence of bacterial infection. While our model did demonstrate significant differences in some cytokines, including IL-1, IL-6, and TNF-a, at certain time points, we did not find any significant differences in the overall trend of the immune response between the vancomycin treated and untreated groups. Both groups demonstrated robust increases in cytokine levels that remained elevated throughout the course of the study, with the exception of IL-12p70.
Despite the findings of our study, there are several important limitations to direct translation of our findings to human patient populations. First, while our model attempts to recreate the physiologic insults of a traumatic, blast-related amputation, it does so in a very controlled, reproducible manner. Inoculation with a single strain of MRSA is deliberate and monomicrobial, whereas typical blast injuries are frequently inundated with environmental debris and chemical contaminants and are generally poly-microbially colonized or infected. 36, 37 Second, combat-wounded patients, due to the nature of their injuries, undergo multiple d ebridement procedures; in one series, patients underwent an average of 4.7 procedures prior to closure. 3 While thorough and unhurried serial d ebridement procedures are necessary to achieve healthy tissue prior to closure, the invasive nature of multiple procedures may contribute to immune dysregulation via a (serially repeated) second-hit phenomenon. Additionally, due to the severity of hemorrhage associated with the typical constellation of injuries sustained from an improvised explosive device blast, many wounded service members receive large or massive blood transfusions shortly after injury. 38 The immunosuppressive and immunomodulatory effects of allogeneic blood transfusions are well-known, 39 but the impact of these phenomena on the resulting wound microbiome and/or subsequent HO formation remains to be elucidated. Vancomycin powder would need to be applied at the time of injury to suppress ectopic bone formation in a combat casualty setting due to its apparent loss of efficacy when delayed until POD-3. Whether or not the vancomycin would need to be reapplied following each d ebridement is a question that remains unanswered by the current study. There is also a theoretical concern that vancomycin treatment may favor development of Gram-negative infections by altering the wound microenvironment. Ghobrial et al. reported an increased proportion of Gram-negative surgical site infections following spinal surgery with prophylactic intraoperative vancomycin treatment. 40 Evidence from civilian trauma studies using early topical vancomycin further suggests that this is the case, although the absolute wound infection rate remains unchanged or slightly reduced. 41 While our findings are promising, they leave a number of questions to be addressed in future studies. We observed a significant decrease in ectopic bone formation when vancomycin was applied at the time of injury compared to 3 days post-injury and so further characterization of treatment timing remains to be performed. Additionally, since vancomycin treatment led to a reduction in ectopic bone formation in both the MRSA infected animals and noninfected animals, it is clear that its effects are not from simply clearing and/or preventing infections. If the mechanism vancomycin is acting through can be identified, this could lead to a broader range of treatment options. Lastly, vancomycin was the only antibiotic included in the present study and so other antimicrobial compounds should be included in future studies.
In conclusion, local vancomycin application at the time of injury leads to significant reduction in ectopic bone formation and effectively eliminates persistent infection. Furthermore, when vancomycin application is delayed there is less reduction of ectopic bone formation and residual infection is more likely to persist.
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